COPD Enters the Biologic Era: Are Your Patients Ready?

COPD has long been managed as a condition to be controlled rather than meaningfully altered. That view is shifting. As research into airway biology has advanced, it has become clear that COPD is a heterogeneous disease, and that targeting the right inflammatory pathway in the right patient can produce outcomes that were not previously possible.Learn more about this episode: http://chroniclungdiseases.com/en/copd-biologic-therapy-practical-guideRESPIPLUS™ received support from Sanofi to develop an informative podcast series specifically tailored to COPD Biologics.Subscribe to The eXpand Podcast: • YouTube: https://bit.ly/eXpandPodcastYouTube• Apple Podcast: https://bit.ly/eXpandPodcastApple• Spotify: https://bit.ly/eXpandPodcastSpotify• Google Podcasts: https://bit.ly/eXpandPodcastGoogle#theexpandpodcast #copdbiologicsCOPD biologics, biologic therapy COPD, dupilumab COPD, COPD treatment, eosinophils COPD, COPD exacerbations, precision medicine COPD, targeted COPD therapy, COPD clinical practice, COPD biomarkers, COPD management, respiratory health, chronic lung disease, COPD physician guide, pulmonary medicine, MPOC biologiques, traitement MPOC, médecine de précision